Generous takeover bids for Tate & Lyle and Spire Healthcare are spotlighting the UK mid-cap sector. Ingredion's £2.7bn offer and a £1bn approach from a top shareholder both exceed 55% premiums, far above the typical 30% markup. This activity contrasts with pervasive gloom that has kept the FTSE 250 valued at 12 times forward earnings, a discount to the US S&P 400 MidCap's 17 times.

Mid-caps drive UK dealmaking, comprising over 60% of bids long-term but three-quarters since 2020. Their domestic focus means they've lagged multinational FTSE 100 peers. Yet a subset of about 52 index companies shows robust top-line growth of at least 10% annually. These include Applied Nutrition, Trainline, and Goodwin, demonstrating appeal beyond current market pessimism.

The valuation gap with US peers may spur more cross-border interest. However, high growth is not guaranteed; Wizz Air's struggles show even fast-expanding firms face headwinds like fuel costs and geopolitical risks. If deal momentum builds, it could lift overall sector valuations, though premiums may retreat from current lofty levels.